Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: A review

Rodney, Tamar; Osier, Nicole Danielle; Gill, Jessica

doi:10.1016/j.cyto.2018.01.012

Cited by 73 publications

(49 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first human study focused on bTBI which includes both preand long-term post-injury cytokine measures. The peripheral inflammatory response that is activated in response to injury is mediated by the complex release of cytokines which facilitate and inhibit inflammatory responses [18,21,52]. IL-β is a pro-inflammatory cytokine whose involvement in neuroinflammation during the acute phase post-injury has been well-described.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blast traumatic brain injury and serum inflammatory cytokines: a repeated measures case-control study among U.S. military service members

Rusiecki

Levin

Wang

et al. 2020

J Neuroinflammation

View full text Add to dashboard Cite

Background: There is a paucity of human data on exposure to blast traumatic brain injury (bTBI) and the corresponding systemic cytokine immune response at later time points (i.e., months, years) post-injury. Methods: We conducted a repeated measures, case-control study, examining associations of serum levels of proand anti-inflammatory cytokines, measured both pre-and post-deployment with having mild and moderate/severe bTBI. Utilizing serum from the Department of Defense Serum Repository cytokines were measured via an ELISAbased array for 15 cytokines. We compared pre-vs. post-levels among mild cases, moderate/severe cases, and controls and carried out case-control comparisons, using paired ttests and generalized linear models. Results: The average time between bTBI and post-deployment/bTBI serum among cases was 315.8 days. From preto post-deployment/bTBI, levels of interleukin 8 (IL-8) were decreased among both mild cases (μ = − 83.43 pg/ml; s.e. = 21.66) and moderate/severe cases (μ = − 107.67 pg/ml; s.e. = 28.74 pg/ml), while levels increased among controls (μ = 32.86 pg/ml; s.e. = 30.29). The same pattern occurred for matrix metallopeptidase 3 (MMP3), with levels decreasing for moderate/severe cases (μ = − 3369.24 pg/ml; s.e. = 1701.68) and increasing for controls (μ = 1859.60 pg/ml; s.e. = 1737.51) from pre-to post-deployment/bTBI. Evidence was also suggestive of case-control differences, from pre-to post-deployment/bTBI for interleukin 1 alpha (IL-1α), interleukin 4 (IL-4), and interleukin 6 (IL-6) among moderate/severe cases. Conclusion: The findings of this longitudinal study indicate that in the chronic phase of bTBI, levels of IL-8 and MMP3 may be substantially lower than pre-injury. These results need confirmation in other studies, potentially those that account for treatment differences, which was not possible in our study.

show abstract

Section: Discussionmentioning

confidence: 99%

“…MMPs, and in particular, MMP3 and MMP9, are upregulated during TBI, because of BBB disruption, and are involved in neuroinflammation and cell death [54]. It is unclear, however, whether inflammation persists over time as measured by serum cytokine levels in the setting of TBI or bTBI [52].…”

Section: Discussionmentioning

confidence: 99%

Blast traumatic brain injury and serum inflammatory cytokines: a repeated measures case-control study among U.S. military service members

Rusiecki

Levin

Wang

et al. 2020

J Neuroinflammation

View full text Add to dashboard Cite

show abstract

“…Inflammation plays a critical role in the pathological progress of TBI and excessive release of proinflammatory cytokines was known to induce secondary brain injury after TBI [6]. Increased levels of proinflammatory cytokines such as IL-1, IL-6, and TNF-α were found to be correlated with worse outcomes after TBI [22], and previous studies found that suppression of proinflammatory cytokines in the CNS by pharmaceuticals or genetic manipulation played beneficial effects in TBI [23]. Isoliquiritigenin was found to possess anti-inflammatory properties and inhibit lipopolysaccharide-induced production of TNF-α and IL-6 in vitro [10].…”

Section: Discussionmentioning

confidence: 99%

Isoliquiritigenin Attenuates Neuroinflammation in Traumatic Brain Injury in Young Rats

Liu

Xiong

Sui

2019

Neuroimmunomodulation

View full text Add to dashboard Cite

Objectives: Inflammation and apoptosis play a critical role in the pathological progress of traumatic brain injury (TBI). Isoliquiritigenin is a bioactive component extracted from licorice roots, which possesses anti-inflammatory and anti-apoptotic properties. This study aims to investigate the potential effects of isoliquiritigenin on neuroinflammation in a rat model of TBI. Methods: The SH-SY5Y cells were subjected to cell injury induced by shear stress and the effect of isoliquiritigenin on cell apoptosis was measured. Male rats received a controlled cortical impact to induce TBI and were then treated with isoliquiritigenin (20 mg/kg). Brain edema and contusion volume were measured to assess brain damage. Morris water maze, the beam-balance test, and the beam-walk test were performed to evaluate the cognitive and motor functions. Results: Levels of proinflammatory cytokines and apoptotic regulators were measured. Results showed that isoliquiritigenin reduced shear stress-induced cell apoptosis in vitro. In young rats subjected to TBI, treatment of isoliquiritigenin reduced brain damage and attenuated motor and cognitive impairments. Isoliquiritigenin also reduced the level of proinflammatory cytokines and Bax and increased Bcl-2 and Bcl-xL in TBI rats. Conclusions: These findings suggest that isoliquiritigenin possesses beneficial effects in TBI by inhibiting inflammation and apoptosis.

show abstract

“…Therefore, an accurate assessment is particularly important for clinical evaluation of traumatic injuries, treatment selection, and prognostic evaluation in patients with TBI. [33][34][35] Regarding basic research on TBI, biomechanical research must accurately evaluate mathematical models of brain tissue mechanical parameters. Due to limited intracranial spatial resolution, US imaging has traditionally been used less frequently for TBI analyses compared with other conventional imaging modalities.…”

Section: Traumatic Brain Injurymentioning

confidence: 99%

Progress in the Application of Ultrasound Elastography for Brain Diseases

Liao

Yang

et al. 2020

J of Ultrasound Medicine

View full text Add to dashboard Cite

Ultrasound (US) can be used to evaluate the brain structure and nervous system damage. Patients with neurologic symptoms need rapid, noninvasive imaging with high spatial resolution and tissue contrast. Magnetic resonance imaging is currently the most sensitive and specific imaging method for evaluating neuropathologic conditions. This approach does present some challenges, such as the need to transport patients who may be seriously ill to the magnetic resonance imaging suite and the need for patients to remain for a considerable time. Cranial US provides a very valuable imaging method for clinicians, which can make a rapid diagnosis and evaluation without ionizing radiation. The main disadvantage of cranial US is its low sensitivity and specificity for subtle/early lesions. In recent years, with the rapid development of anatomic and functional US technology, the practicability of US diagnosis and intervention has been greatly improved. Ultrasound elastography may have the potential to improve the sensitivity and specificity of various cranial nerve conditions. Ultrasound elastography has received considerable critical attention, and an increasing number of studies have recognized its critical role in evaluating brain diseases. At present, US elastography has been applied to the evaluation of traumatic brain injury, ischemic stroke, intraoperative brain tumors, and hypoxic ischemic encephalopathy. The latest animal experiments and human clinical trial developments in the applications of US elastography for brain diseases are summarized in this review.

show abstract

Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: A review

Cited by 73 publications

References 40 publications

Blast traumatic brain injury and serum inflammatory cytokines: a repeated measures case-control study among U.S. military service members

Blast traumatic brain injury and serum inflammatory cytokines: a repeated measures case-control study among U.S. military service members

Isoliquiritigenin Attenuates Neuroinflammation in Traumatic Brain Injury in Young Rats

Progress in the Application of Ultrasound Elastography for Brain Diseases

Contact Info

Product

Resources

About